Official Website: Nusano
source confidence: Medium status: Useful updated 2026-06-18
Summary
Nusano's official website describes a physics company building accelerator-based radioisotope production for medical, energy, and critical-minerals applications. Its flagship production facility is in West Valley City, Utah.
Useful Claims
- Nusano supplies medical radioisotopes to drugmakers, hospitals, and clinics, targeting undersupplied markets for radiotherapeutics and diagnostics.
- The company combines patented particle-acceleration technology with established production methods to make radioisotopes at commercial scale.
- West Valley City, Utah is named as the site of a state-of-the-art production facility bringing high-tech jobs to the Salt Lake Valley.
- Beyond life sciences, the site describes applications in clean energy (accelerating decay of long-lived nuclear waste) and critical minerals recovery.
- Nusano frames its role as enabling infrastructure for next-generation cancer therapies dependent on isotopes such as those used in targeted radiopharmaceuticals.
Verbatim
"Nusano's role in the health care ecosystem is as a supplier of medical radioisotopes to drugmakers, hospitals and clinics." — Home page, life sciences section
"Nusano is combining time-tested methods with our own breakthrough, patented particle acceleration technology, so we can produce radioisotopes quickly, efficiently, and affordably." — Home page, technology section
"Nusano is building a state-of-the-art production facility in Utah's Salt Lake Valley. It will not only create radioisotopes needed by health care, industry and researchers, but also bring new, high-tech jobs to the area." — Home page, "West Valley City, Utah"
"Radioisotopes are essential components in the active pharmaceutical ingredients (API) of a category of new and emerging cancer therapies, known as radiotherapeutics." — Home page, life sciences section
Reliability Notes
Official company source — useful for mission, technology framing, and Utah facility location. Production timelines, isotope menu breadth (40+ isotopes cited in press coverage), funding totals, and cGMP qualification status should be corroborated with facility-opening press releases, regulatory filings, and customer agreements. Ownership and Series C details are partially public but incomplete.